137 related articles for article (PubMed ID: 15009621)
1. Preoperative serum inhibin levels in patients with ovarian tumors.
El-Shalakany A; Abou-Talib Y; Shalaby HS; Sallam M
J Obstet Gynaecol Res; 2004 Apr; 30(2):155-61. PubMed ID: 15009621
[TBL] [Abstract][Full Text] [Related]
2. A comparative study of serum alpha-beta A immunoreactive inhibin and tumor-associated antigens CA125 and CEA in ovarian cancer.
Phocas I; Sarandakou A; Sikiotis K; Rizos D; Kalambokis D; Zourlas PA
Anticancer Res; 1996; 16(6B):3827-31. PubMed ID: 9042265
[TBL] [Abstract][Full Text] [Related]
3. Total inhibin is a potential serum marker for epithelial ovarian cancer.
Tsigkou A; Marrelli D; Reis FM; Luisi S; Silva-Filho AL; Roviello F; Triginelli SA; Petraglia F
J Clin Endocrinol Metab; 2007 Jul; 92(7):2526-31. PubMed ID: 17473066
[TBL] [Abstract][Full Text] [Related]
4. Characterization of inhibin forms and their measurement by an inhibin alpha-subunit ELISA in serum from postmenopausal women with ovarian cancer.
Robertson DM; Stephenson T; Pruysers E; McCloud P; Tsigos A; Groome N; Mamers P; Burger HG
J Clin Endocrinol Metab; 2002 Feb; 87(2):816-24. PubMed ID: 11836327
[TBL] [Abstract][Full Text] [Related]
5. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
[TBL] [Abstract][Full Text] [Related]
6. Pre-operative prediction of serum CA125 level in women with ovarian masses.
Benjapibal M; Neungton C
J Med Assoc Thai; 2007 Oct; 90(10):1986-91. PubMed ID: 18041413
[TBL] [Abstract][Full Text] [Related]
7. Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer.
Arits AH; Stoot JE; Botterweck AA; Roumen FJ; Voogd AC
Int J Gynecol Cancer; 2008; 18(4):621-8. PubMed ID: 17868339
[TBL] [Abstract][Full Text] [Related]
8. Comparison of risk of malignancy index (RMI), CA125, CA 19-9, ultrasound score, and menopausal status in borderline ovarian tumor.
Alanbay I; Akturk E; Coksuer H; Ercan M; Karaşahin E; Dede M; Yenen MC; Ozan H; Baser I
Gynecol Endocrinol; 2012 Jun; 28(6):478-82. PubMed ID: 22122561
[TBL] [Abstract][Full Text] [Related]
9. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer.
Cooper BC; Ritchie JM; Broghammer CL; Coffin J; Sorosky JI; Buller RE; Hendrix MJ; Sood AK
Clin Cancer Res; 2002 Oct; 8(10):3193-7. PubMed ID: 12374688
[TBL] [Abstract][Full Text] [Related]
10. Preoperative detection of ovarian cancer by color Doppler ultrasonography and CA 125.
Hossain F; Karim MN; Rahman SM; Khan N; Siddiqui M; Hussain R
Bangladesh Med Res Counc Bull; 2010 Aug; 36(2):68-73. PubMed ID: 21473205
[TBL] [Abstract][Full Text] [Related]
11. Studies on angiogenesis in the benign and malignant ovarian neoplasms with the use of color and pulsed Doppler sonography and serum CA-125, CA-19.9, CA-72.4 and vascular endothelial growth factor measurements.
Czekierdowski A
Ann Univ Mariae Curie Sklodowska Med; 2002; 57(1):113-31. PubMed ID: 12898913
[TBL] [Abstract][Full Text] [Related]
12. Ascites as a predictor of ovarian malignancy.
Shen-Gunther J; Mannel RS
Gynecol Oncol; 2002 Oct; 87(1):77-83. PubMed ID: 12468346
[TBL] [Abstract][Full Text] [Related]
13. Serum neopterin levels in ovarian tumors.
Park IS; Lee YS; Kim JC; Hwang SG
Int J Gynaecol Obstet; 1995 Dec; 51(3):229-34. PubMed ID: 8745088
[TBL] [Abstract][Full Text] [Related]
14. Inhibins and ovarian cancer.
Robertson DM; Pruysers E; Burger HG; Jobling T; McNeilage J; Healy D
Mol Cell Endocrinol; 2004 Oct; 225(1-2):65-71. PubMed ID: 15451569
[TBL] [Abstract][Full Text] [Related]
15. [Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma].
Wang MJ; Qi J; Wang H; Li XX; Wei BJ; Fu C; Gao J; Han BB
Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):540-3. PubMed ID: 22093635
[TBL] [Abstract][Full Text] [Related]
16. Preoperative measurement of serum C-reactive protein: is it useful in the differential diagnosis of adnexal masses?
Yoshida A; Derchain SF; Pitta DR; Crozatti N; Andrade LALA; da Silva RF; Sarian LO
Int J Biol Markers; 2017 Mar; 32(1):e83-e89. PubMed ID: 27516000
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of serum mesothelin in malignant and benign ovarian masses.
Ibrahim M; Bahaa A; Ibrahim A; El Hakem AA; Abo-El Noor A; El Tohamy U
Arch Gynecol Obstet; 2014 Jul; 290(1):107-13. PubMed ID: 24445964
[TBL] [Abstract][Full Text] [Related]
18. Inhibin A, B and pro-alphaC in serum and peritoneal fluid in postmenopausal patients with ovarian tumors.
Ala-Fossi SL; Mäenpää J; Bläuer M; Tuohimaa P; Punnonen R
Eur J Endocrinol; 2000 Apr; 142(4):334-9. PubMed ID: 10754473
[TBL] [Abstract][Full Text] [Related]
19. Combined inhibin and CA125 assays in the detection of ovarian cancer.
Robertson DM; Cahir N; Burger HG; Mamers P; McCloud PI; Pettersson K; McGuckin M
Clin Chem; 1999 May; 45(5):651-8. PubMed ID: 10222351
[TBL] [Abstract][Full Text] [Related]
20. Significance of CA 125 serum level in discrimination between benign and malignant masses in the pelvis.
Milojkovic M; Hrgovic Z; Hrgovic I; Jonat W; Maass N; Buković D
Arch Gynecol Obstet; 2004 Mar; 269(3):176-80. PubMed ID: 14557888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
